Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ACT [NYSE]
Actavis plc
IndexS&P 500 P/E492.36 EPS (ttm)0.47 Insider Own0.40% Shs Outstand264.26M Perf Week6.52%
Market Cap61.15B Forward P/E14.13 EPS next Y16.38 Insider Trans33.80% Shs Float263.12M Perf Month-3.92%
Income62.40M PEG23.12 EPS next Q3.10 Inst Own69.20% Short Float0.78% Perf Quarter5.82%
Sales10.11B P/S6.05 EPS this Y-793.40% Inst Trans2.53% Short Ratio0.85 Perf Half Y14.20%
Book/sh55.57 P/B4.16 EPS next Y23.23% ROA0.30% Target Price267.52 Perf Year57.54%
Cash/sh16.26 P/C14.23 EPS next 5Y21.30% ROE0.80% 52W Range143.71 - 249.94 Perf YTD37.74%
Dividend- P/FCF41.26 EPS past 5Y-35.20% ROI-3.00% 52W High-7.41% Beta0.37
Dividend %- Quick Ratio1.60 Sales past 5Y27.90% Gross Margin49.10% 52W Low61.03% ATR7.91
Employees19200 Current Ratio2.00 Sales Q/Q34.00% Oper. Margin15.20% RSI (14)48.73 Volatility3.38% 3.31%
OptionableYes Debt/Eq1.27 EPS Q/Q106.60% Profit Margin0.60% Rel Volume0.68 Prev Close232.13
ShortableYes LT Debt/Eq1.11 EarningsNov 05 BMO Payout0.00% Avg Volume2.43M Price231.41
Recom1.60 SMA20-2.03% SMA500.06% SMA2009.03% Volume1,648,300 Change-0.31%
22-Sep-14Downgrade Barclays Overweight → Equal Weight $250 → $250
06-Aug-14Reiterated UBS Buy $237 → $254
02-Jul-14Reiterated CRT Capital Buy $245 → $275
27-Jun-14Initiated Canaccord Genuity Buy $275
12-May-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
01-May-14Reiterated CRT Capital Buy $230 → $245
28-Apr-14Reiterated National Alliance Securities Buy $246 → $259
17-Apr-14Initiated National Alliance Securities Buy $246
21-Feb-14Reiterated RBC Capital Mkts Outperform $240 → $249
19-Feb-14Reiterated UBS Buy $202 → $237
19-Feb-14Reiterated CRT Capital Buy $210 → $230
19-Feb-14Reiterated Barclays Overweight $230 → $250
03-Feb-14Reiterated RBC Capital Mkts Outperform $202 → $222
03-Feb-14Reiterated Barclays Overweight $190 → $230
17-Jan-14Reiterated Argus Buy $180 → $198
07-Jan-14Initiated RBC Capital Mkts Outperform $202
30-Oct-13Reiterated Barclays Overweight $175 → $190
16-Sep-13Reiterated Barclays Overweight $140 → $175
30-Jul-13Reiterated Argus Buy $120 → $150
26-Jul-13Reiterated CRT Capital Buy $140 → $150
22-Oct-14 05:53PM  Illumina Breaks Out Of Double-Bottom Base at Investor's Business Daily
08:30AM  Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin PR Newswire
07:22AM  Akorn (AKRX) Looks Good: Stock Adds 5.8% in Session Zacks
20-Oct-14 06:08PM  Actavis, Sanofi among bidders for Omega Pharma - Bloomberg Reuters
05:14PM  Actavis Said to Compete With Sanofi for Omega Pharma Deal at Bloomberg
01:53PM  Top Allergan holder Paulson urges deal with Shire -sources Reuters
17-Oct-14 06:36PM  Akorn Finds Institutional Support In Base at Investor's Business Daily
05:00PM  Why Magnetar Capital exits position in Rosetta Resources Market Realist
03:40PM  Ironwood/Actavis Move Linzess into Phase II Study for OIC Zacks
09:00AM  Why Magnetar Capital initiates new position in Actavis Market Realist
16-Oct-14 11:10AM  Will Actavis Win Competition For Allergan's Affection? Benzinga
08:00AM  Actavis Confirms Generic Quillivant XR® Patent Challenge PR Newswire
01:22AM  AbbVie Board To Shareholders: Vote No On Shire Buy at Investor's Business Daily
15-Oct-14 05:12PM  Stocks Pare Losses; Netflix Plunges After Hours at Investor's Business Daily
04:10PM  Mallinckrodt Gives FY15 Guidance Post Questcor Acquisition Zacks
03:29PM  Stocks Slump Again Heading Into Close at Investor's Business Daily
12:42AM  [$$] Ireland to Close Double Irish Tax Loophole at The Wall Street Journal
14-Oct-14 05:46PM  [$$] Ireland to Close Tax Loophole at The Wall Street Journal
01:10PM  Drug Analysts Mull End Of 'Double Irish' Loophole at Investor's Business Daily
13-Oct-14 07:14AM  Zacks Rank #1 Additions for Monday Zacks -5.84%
06:14AM  AxoGen (AXGN) Shows Strength: Stock Up 15.4% in Session Zacks
10-Oct-14 04:52PM  Impax Up, Set to Buy Tower Holdings & Lineage Therapeutics Zacks
08:03AM  Impax Laboratories Inc. (IPXL) in Focus: Stock Rises 11.8% Zacks
09-Oct-14 05:05PM  Indexes Slammed As Oil Prices, Stocks Sink at Investor's Business Daily
03:45PM  Teva Starts Rolling Submission of its Pain Drug CEP-33237 Zacks
03:10PM  Ligand Provides Better-than-Expected Q3 Earnings Guidance Zacks
11:56AM  Allergan Steeply Raises Guidance, Taunts Valeant at Investor's Business Daily
08:00AM  Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting Business Wire
07:51AM  Allergan raises outlook; says Valeant offer undervalues company Reuters
08-Oct-14 06:30PM  Actavis deal for Allergan would be huge bet on branded drugs Reuters
01:30PM  Allergan: Three's Company at Financial Times
12:52PM  Dealpolitik: Allergan Battle May Showcase Unintended Consequences of Inversion Rules at The Wall Street Journal
09:05AM  Yum China sales not so yummy; Costco tops estimates; Symantec jumps on breakup talk Hot Stock Minute
09:01AM  Stock Futures Aim For A Bounce; Symantec Up On Split Reports at Investor's Business Daily
07:57AM  Investors look to Fed minutes; Yum's profits slammed; Twitter sues U.S. Hot Stock Minute
06:08AM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
04:50AM  Exclusive: Actavis plans new merger approach for Allergan - sources Reuters
07-Oct-14 07:33PM  Salix, Actavis Among Big Cap Pharmas In Merger Mambo at Investor's Business Daily
06:33PM  Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene at Investor's Business Daily
06:08PM  Actavis, Jazz, Novo Lead Top World Stocks List at Investor's Business Daily
05:10PM  Teva to Concentrate on Core Specialty Therapeutics Zacks
04:34PM  INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata Therapeutics Inc. Regarding the Fairness of the Sale of the Company to Actavis - ACT PR Newswire
04:05PM  Progenics Gets $40M Milestone on FDA Approval of Relistor Zacks
03:48PM  Salix: The Field of Potential Buyers is Vast, Analyst Says at The Wall Street Journal
03:05PM  Actavis plans new Allergan approach: Report CNBC
03:05PM  [video] Actavis plans new Allergan approach: Report at CNBC
10:43AM  INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis -- DRTX PR Newswire
09:29AM  Stock Market News for October 07, 2014 Zacks
06-Oct-14 06:08PM  Generics Firms Step Up Their Game In Branded Drugs at Investor's Business Daily
04:38PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:25PM  Supernus Up, Files Lawsuit against Actavis for Trokendi XR Zacks
12:46PM  Midday movers: Chimerix, H&R Block, McDonald's & More at CNBC
12:38PM  Will Biotech Beat This Earnings Season? at Barrons.com
12:34PM  [$$] Actavis to Buy Antibiotic Maker at The Wall Street Journal
11:34AM  DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
10:58AM  Actavis Expands Antibiotics Presence With Durata Buy at Investor's Business Daily
10:20AM  Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today at TheStreet
09:47AM  Better-than-expected jobs data helped benchmarks end in the green on Friday Zacks
08:44AM  Actavis agrees to acquire Durata Therapeutics at MarketWatch
08:34AM  Actavis buying Durata Therapeutics for $616.4 AP
08:32AM  Actavis to Buy Durata for $675 Million for Antibiotic at Bloomberg
08:00AM  Actavis to Acquire Durata Therapeutics, Inc. PR Newswire
03-Oct-14 04:31PM  Strong JOBS = Strong MARKETS Yahoo Finance Blogs
02:37PM  Some ETFs Saying a Salix Takeover Could be Afoot ETF Trends
01:32PM  Nasdaq, S&P 500 Aim For 50-Day Lines; Alexion Breaks Out at Investor's Business Daily
11:11AM  Salix Cancels Tax Inversion, Opens Way For Buyers at Investor's Business Daily
02-Oct-14 06:25PM  Top Fund Buys: Chipotle, Allergan, Jazz, Gilead at Investor's Business Daily
06:06PM  Salix Said in Talks to Sell to Actavis as Allergan Fades at Bloomberg
01-Oct-14 04:20PM  Actavis in Patent Infringement Lawsuit for Purdue's Butrans Zacks
12:10PM  Ardelyx Bowel Drug Could Rival Actavis' Linzess at Investor's Business Daily
09:47AM  I'm Shocked, Shocked To Find That Pharma Is Paying Doctors! at Forbes
30-Sep-14 06:24PM  Ireland Exporters Look To Thursday's ECB Policy Vote at Investor's Business Daily
08:00AM  Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast PR Newswire
06:01AM  ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
29-Sep-14 01:03PM  AMGN, ACT And GILD, Pushing Drugs Industry Downward at TheStreet
12:34PM  Where the Allergan-Valeant(-Salix-Actavis-Teva) Fights Stand Now at The Wall Street Journal
12:07PM  Five Reasons Celgene Could Gain 20% at Barrons.com
27-Sep-14 08:02AM  Facebook Among 5 IBD 50 Stocks Holding Near Highs at Investor's Business Daily
26-Sep-14 04:04PM  Allergan Shareholder T. Rowe Price Criticizes Board at Bloomberg
09:21AM  AbbVie Said to Weigh More Shire Financing After U.S. Rule at Bloomberg
06:01AM  Next for Jeter Is Straightening Those Bent IPhones: Opening Line at Bloomberg
25-Sep-14 05:39PM  Today's Market Thorns, Roses, and All Time Highs... Plus an Extra... Yahoo Finance Blogs
04:05PM  Actavis Confirms Generic Butrans® Patent Challenge PR Newswire
24-Sep-14 11:36PM  Facebook, Three Other Leaders In Striking Distance at Investor's Business Daily
05:49PM  Valeant Grows Bullish On Q3 Sales While Allergan's Defense Weakens Investor's Business Daily
05:05PM  Actavis to keep selling Alzheimer's drug in U.S. for 60 days Reuters
03:53PM  Taking Stock: Sherman, Eisenberg Discuss Tax Inversion at Bloomberg
12:47PM  [$$] Pfizer Held Takeover Talks With Actavis at The Wall Street Journal
11:51AM  Actavis reportedly in talks to buy Salix Pharma at MarketWatch
11:11AM  Salix contacts Actavis over potential sale-source Reuters
10:27AM  Pfizer Seeking Inversions Shows Companies Unfazed by Lew Bloomberg
10:19AM  Actavis in buyout talks with Salix: CNBC Reuters
09:01AM  Faber: Actavis pursues Salix CNBC
09:01AM  [video] Faber: Actavis pursues Salix at CNBC
08:00AM  Pfizer, Actavis Rumor, Inversion Turn Attention to Pharma ETFs ETF Trends
04:56AM  [video] Pfizer Looks Outside U.S. Despite New Tax Rules at Bloomberg
02:31AM  Pfizer explored deal with rival Actavis: Report at CNBC
23-Sep-14 06:06PM  Stocks Finish Lower Among Takeover Rumors at Investor's Business Daily
05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
22-Sep-14 07:46AM  Global literacy challenge CNBC
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.